Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Mar 7;107(3):487–498. doi: 10.1016/j.ijrobp.2020.02.031

Fig. 1.

Fig. 1.

MEDI0457 and chemoradiation is associated with cellular immune responses against HPV 16 or HPV 18 E6/E7 antigens in the majority of patients with cervical cancer treated with chemoradiation. Log scale plots on IFNγ ELISpot assays of PBMC taken at various time points after MEDI0457 immunizations. On day 0, patients received MEDI0457 followed by EP (arrows) beginning 2 to 4 weeks after chemoradiation. MEDI0457 was given every 4 weeks for a total of 4 injections. PBMCs were collected beginning on day 0 and at weeks 2, 4, 6, 8, 10, 12, 14, 16, 24, 32, 36, 40, and 48. PBMCs were assayed for IFNγ production in response to E6E7 peptides by ELISpot. Data represent the combined ELISpot results for HPV16 and HPV18 E6 and E7 peptide stimulations (represented as SFU/106 PBMCs). Each line/color represents a patient. Half-filled symbols (n = 3) represent HPV18 detected at screening, open symbols (n = 7) represent HPV16 detected at screening. Abbreviations: ELISpot = enzyme-linked immunosorbent spot; EP = electroporation; HPV = human papilloma virus; IFNγ = interferon gamma; PBMCs = peripheral blood mononuclear cell; SFU = spot forming units.